In conclusion, purinergic receptors have emerged as promising therapeutic targets to promote physiological saliva flow, prevent salivary gland inflammation and enhance tissue regeneration required to reverse common causes of salivary gland dysfunction in humans, such as the autoimmune disease SS or the side effect of radiotherapy in head and neck cancer patients. Here, P2RX4 is linked to synovial sarcoma.